RxDoctor Payments Data

Mark Bernhard, MD

Family Medicine · Fort Worth, TXNPI 1912924515

Payments from drug & device makers

$1,491in general payments, 2019–2025

Across 59 payments — averaging $25.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$288
  • Bayer$227
  • Inspire Medical Systems, Inc.$201
  • GSK$150
  • AstraZeneca$131
  • Abbott$124
  • plus $371 from 11 others

What the payments were for

  • Food & beverage$1,491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,491 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$20,346
Medicare patients
133
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$91,430
EliquisApixaban32$42,215
OzempicSemaglutide25$29,689
JanuviaSitagliptin Phosphate25$29,494
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,592
Breo ElliptaFluticasone/Vilanterol20$18,060
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$17,531
JanumetSitagliptin Phos/Metformin Hcl18$17,310
ArexvyRsvpref3 Antigen/As01e/Pf41$12,797
ShingrixVaricella-Zoster Ge/As01b/Pf49$10,889
SymbicortBudesonide/Formoterol Fumarate30$9,971
Humalog Kwikpen U-100Insulin Lispro19$6,434
Boostrix TdapDiphth,pertuss(Acell),tet Vac92$6,413
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$6,172
AbrysvoRsv Vacc, Pref A And Pref B/Pf17$5,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$87$91,43061 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$150$65,338138 claims
PfizerEliquis, Abrysvo$18$47,60149 claims
Novo NordiskOzempic$288$29,68925 claims
AstraZenecaSymbicort$131$9,97130 claims
AbbVieSynthroid$19$2,92625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →